The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Effect of time to relapse on overall survival (OS) in Mantle cell lymphoma (MCL) patients (pts) following frontline high-dose therapy and autologous hematopoietic cell transplantation (autoHCT).
 
Peter A. Riedell
Honoraria - Novartis
Consulting or Advisory Role - Bayer; BeiGene; Celgene/Bristol-Myers Squibb; Karyopharm Therapeutics; Novartis; Takeda
Speakers' Bureau - Bayer; Kite/Gilead
Research Funding - Calibr; Celgene/Bristol-Myers Squibb; Kite/Gilead; MorphoSys; Novartis
Travel, Accommodations, Expenses - Novartis
 
Mehdi Hamadani
Honoraria - Celgene
Consulting or Advisory Role - ADC Therapeutics; Cellerant Therapeutics; Incyte; Janssen Research & Development; MedImmune; Pharmacyclics; Puma Biotechnology (I); Verastem
Speakers' Bureau - AstraZeneca; Celgene; Genzyme
Research Funding - Astellas Pharma; Genzyme; Genzyme; Otsuka; Spectrum Pharmaceuticals; Takeda
 
Kwang Woo Ahn
No Relationships to Disclose
 
Carlos Litovich
No Relationships to Disclose
 
Mohamed Kharfan-Dabaja
Consulting or Advisory Role - Daiichi Sankyo; Pharmacyclics
 
Alex Francisco Herrera
Consulting or Advisory Role - Bristol-Myers Squibb; Kite, a Gilead company; Seagen
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Genentech/Roche (Inst); Gilead Sciences (Inst); Immune Design (Inst); Kite, a Gilead company (Inst); Merck (Inst); Pharmacyclics (Inst); Seagen (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb
 
Craig Steven Sauter
Consulting or Advisory Role - Celgene/Bristol-Myers Squibb; Gamida Cell; Genmab; GlaxoSmithKline; Juno Therapeutics; Karyopharm Therapeutics; Kite/Gilead; Novartis; Precision BioSciences; Sanofi; Spectrum Pharmaceuticals
Research Funding - Bristol-Myers Squibb; Celgene/Bristol-Myers Squibb; Genzyme; Juno Therapeutics; Precision BioSciences
 
Sonali M. Smith
Consulting or Advisory Role - Abbvie/Genentech; Bayer; Janssen Oncology; Karyopharm Therapeutics; Kite, a Gilead company; Seagen; TG Therapeutics
Research Funding - Acerta Pharma/AstraZeneca; Celgene; Forty Seven; Novartis; Pharmacyclics/Janssen; Portola Pharmaceuticals; TG Therapeutics
Other Relationship - Karyopharm Therapeutics